Sign up
Pharma Capital

Redfund Capital Corp bolsters client list with edibles cannabis brand, Winterlife Cannabis

The Seattle-based company is hailed for its high-potency cookies and tinctures
Winterlife Cannabis' product line includes gourmet cookies, tinctures, capsules and more

Redfund Capital Corp. (CSE:COPR) today announced an exciting new client in its pot of gold client list: Winterlife Cannabis.

Redfund, previously under the name Parana Copper Corp, is a cannabis merchant bank that provides alternative funding through a debt facility to companies.

READ: ‘Cannabis 2.0 is here’: Redfund Capital fires up to serve maturing cannabis market

"Our investment will give Winterlife the ability to increase their SKUs and develop brand awareness for their product,” said chief executive officer, Meris Kott.

“The future of cannabis edibles whether drink mixers or cookies is in their brands just like other food items. Winterlife has already succeeded with its unique packaging and catchy animal themed product lines in developing their own consumer following,” she added. 

Not your grandma’s cookies

Winterlife is an internationally recognized cannabis edibles company based in Seattle, and available at more than 400 dispensaries in Washington State.

Its current product line includes gourmet cookies (vegan and gluten free), flavoured cocktail spikers, tinctures and capsules and specialty flower products.

With one of its catchy taglines being, “Edibles don’t have to taste like grass,” the company offers a proprietary extraction and processing method, which allows it to produce high potency extracts. In short? You taste the edibles, not the pot.

Brand expansion ahead

Currently, the company is focused on expanding its brand and positioning itself as recognized, established and trusted brand in the cannabis industry.

“B2B and B2C is all about branding and we cannot wait to see Winterlife Cannabis on shelves in dispensaries in every country that embraces recreational cannabis adult usage," said Kott.

Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.